PixarBio (CE) Stock Price

0.00 (0.0%)


52 Week Range


Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
PixarBio Corporation (CE) PXRB OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.001 20:00:00
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
0.001 0.001 0.00 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.001 USD

PixarBio (CE) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 81.51k 81.51M 1.68M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
80.00 $ - - - -

more financials information »

PixarBio (CE) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PXRB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.0010.0010.0010.0011,3330.000.0%
3 Months0.00020.0010.00020.00091593,3300.0008400.0%
6 Months0.00010.0010.00010.00068422,6580.0009900.0%
1 Year0.00010.0010.00010.00029643,6890.0009900.0%
3 Years0.060.070.0000010.0168942,582-0.059-98.33%
5 Years3.0030.000.0000014.835,994-3.00-99.97%

PixarBio (CE) Description

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain. PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson's disease, and spinal cord injury. Our lead product platform, NeuroRelease, is an extended drug release microparticle platform that is non-opiate, non-addictive for post-surgical pain treatment. In pre-clinical models NeuroRelease has the potential to achieve 6 months of sustained therapeutic release of non-opiate drugs for post-operative, acute and chronic pain.

Your Recent History
PixarBio (..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.